INOA-002 is under clinical development by Inovio Pharmaceuticals and currently in Phase I for Dengue Fever. According to GlobalData, Phase I drugs for Dengue Fever have a 52% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how INOA-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
INOA-002 is under development for the treatment of Zika virus infections, dengue fever and coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The therapeutic candidate is developed using DNA-based monoclonal antibody technology platform in which DNA sequence of a monoclonal antibody is encoded in a DNA (nucleic acid) plasmid and delivered directly into cells using electroporation device. It is administered through intramuscular route.
Inovio Pharmaceuticals overview
Inovio Pharmaceuticals (Inovio) is a biotechnology company that focuses on developing DNA immunotherapies and vaccines for the treatment and prevention of various cancers and infectious diseases. The company develops products based on its core SynCon DNA plasmid technology and electroporation delivery technology. Its product pipeline includes VGX-3100 for the treatment of cervical HSIL, vulvar HSIL, anal HSIL; INO-5401 for glioblastoma; and INO-3107 for recurrent respiratory papillomatosis (RRP). The company is also engaged in development programs in partnership with several companies and government bodies to develop therapeutics for infectious diseases such as HIV, Ebola, Zika virus, Middle East respiratory syndrome (MERS), Lassa fever and COVID-19. Inovio is headquartered in Plymouth Meeting, Pennsylvania, the US.
For a complete picture of INOA-002’s drug-specific PTSR and LoA scores, buy the report here.